Loading...

Purified anti-human CD3 Antibody Purified anti-human CD3 Antibody

Pricing & Availability
Clone
OKT3 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T3, CD3ε
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT3_Purified_053107
Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
  • OKT3_Purified_053107
    Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
317301 25 µg NOK248
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317302 100 µg NOK454
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Hawley KM, et al. 2022. Proc Natl Acad Sci U S A. 119:e2209044119. PubMed
  2. Sun X, et al. 2023. Cell Death Dis. 14:242. PubMed
  3. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  4. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
  5. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  6. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  7. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  8. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  9. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  10. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  11. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  12. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  13. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  14. Jeong H, et al. 2008. J Leukoc Biol. 83:755. PubMed
  15. Biggs M, et al. 2011. J R Soc Interface. 1.348611111. PubMed
  16. Blas-Rus N, et al. 2016. Nat Commun. 7: 11389. PubMed
  17. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  18. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  19. Berkson JD, et al. 2020. Immunohorizons. 4:14. PubMed
  20. Mehta N, et al. 2020. Sci Rep. 10:15171. PubMed
  21. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  22. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  23. Bae EA, et al. 2018. Cancer Res. 78:5315. PubMed
  24. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  25. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  26. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  27. Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed
  28. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  29. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  30. Yarzabek B et al. 2018. eLife. 7 pii: e34961. PubMed
  31. Lang C, Wang J, and Chen L 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.09.030. PubMed
  32. Willimsky G, et al. 2021. Elife. 10:. PubMed
  33. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  34. García–Ortiz A, et al. 2017. PLoS Biol. 15:e2000653. PubMed
  35. Kujawski M, et al. 2019. BMC Cancer. 1.404166667. PubMed
  36. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  37. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  38. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  39. Dilchert J, et al. 2022. Antibodies (Basel). 11:. PubMed
  40. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  41. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  42. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  43. Fu Z, et al. 2021. Acta Pharm Sin B. 11:3925. PubMed
  44. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  45. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
  46. Xiong Y, et al. 2019. J Immunol. 203:3023. PubMed
  47. Kessel C, et al. 2017. Arthritis Rheumatol. 69:1480. PubMed
  48. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  49. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  50. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  51. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  52. Broos K, et al. 2019. Cancers (Basel). 11. PubMed
  53. Zhao R, et al. 2018. Oncoimmunology. 8:e1509173. PubMed
  54. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  55. Kim G, et al. 2021. J Infect Dis. 224:1861. PubMed
  56. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  57. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  58. Johnston HE, et al. 2018. Mol Cell Proteomics. 1.247222222. PubMed
  59. Thomi R, et al. 2017. Br J Dermatol.. 10.1111/bjd.15458. PubMed
  60. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  61. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  62. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  63. Zuñiga J, et al. 2020. Int J Infect Dis. 94:4. PubMed
  64. Wang Q, et al. 2020. J Immunother Cancer. 8:. PubMed
  65. Glud EN, et al. 2022. Br J Cancer. Online ahead of print. PubMed
  66. Mayer KE, et al. 2019. Theranostics. 4.548611111. PubMed
  67. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
  68. Alter G, et al. 2008. J Virol. 82:9668. PubMed
  69. Pinto J, et al. 2010. Immunology. 130:217. PubMed
  70. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  71. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  72. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  73. Guo J, et al. 2022. J Immunother Cancer. 10:. PubMed
  74. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  75. Rivera-Cruz CM, et al. 2022. Cytotherapy. Online ahead of print. PubMed
  76. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  77. Schoknecht T, et al. 2017. J Leukoc Biol. 101:589. PubMed
  78. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
  79. Park S, et al. 2020. Biosens Bioelectron. 112389:165. PubMed
  80. Henrick BM, et al. 2021. Cell. . PubMed
  81. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  82. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  83. Bacot SM, et al. 2020. Int J Mol Sci. 21:. PubMed
  84. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  85. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  86. Manevich-Mendelson E, et al. 2009. Blood. 114:2344. PubMed
  87. Caielli S, et al. 2019. Nat Med. 25:75. PubMed
  88. Ardain A, et al. 2019. Nature. 570:528. PubMed
  89. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  90. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  91. Carriche GM, et al. 2021. J Allergy Clin Immunol. 147:335. PubMed
  92. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  93. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  94. Meng Q, et al. 2018. Sci Rep. 8:17079. PubMed
  95. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  96. Chevalier MF, et al. 2017. J Clin Invest. 127:2916. PubMed
  97. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  98. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  99. Müller TR, et al. 2021. Cell Rep Med. 2:100374. PubMed
  100. Benabdallah B, et al. 2019. Front Immunol. 10:2580. PubMed
  101. Sneddon S, et al. 2020. Oncoimmunology. 9:1684713. PubMed
  102. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
  103. Naranbhai V, et al. 2022. Cell. . PubMed
  104. Yang J, et al. 2020. Nat Commun. 11:4402. PubMed
  105. Crome SQ, et al. 2017. Nat Med. 1.213888889. PubMed
  106. Hashimoto M, et al. 2017. Int J Inflam. 2017:1324735. PubMed
  107. Siegers GM, et al. 2020. Front Immunol. 1.352083333. PubMed
  108. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  109. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  110. He Y, et al. 2021. eLife. 10:00. PubMed
  111. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  112. Yin Y, et al. 2017. J Allergy Clin Immunol. 139:1701. PubMed
  113. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  114. Liu Z, et al. 2017. Oncotarget. 8:53518. PubMed
  115. Terzuoli E, et al. 2019. Cancers (Basel). 1.821527778. PubMed
  116. Welch JL, et al. 2020. FEBS Lett. 594:695. PubMed
  117. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  118. Shalata W, et al. 2021. Cancers (Basel). 13: . PubMed
  119. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  120. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
  121. Hawley KM, et al. 2022. Proc Natl Acad Sci U S A. 119:e2209044119. PubMed
  122. Sun X, et al. 2023. Cell Death Dis. 14:242. PubMed
  123. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  124. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
  125. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  126. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  127. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  128. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  129. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  130. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  131. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  132. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  133. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  134. Jeong H, et al. 2008. J Leukoc Biol. 83:755. PubMed
  135. Biggs M, et al. 2011. J R Soc Interface. 1.348611111. PubMed
  136. Blas-Rus N, et al. 2016. Nat Commun. 7: 11389. PubMed
  137. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  138. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  139. Berkson JD, et al. 2020. Immunohorizons. 4:14. PubMed
  140. Mehta N, et al. 2020. Sci Rep. 10:15171. PubMed
  141. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  142. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  143. Bae EA, et al. 2018. Cancer Res. 78:5315. PubMed
  144. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  145. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  146. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  147. Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed
  148. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  149. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  150. Yarzabek B et al. 2018. eLife. 7 pii: e34961. PubMed
  151. Lang C, Wang J, and Chen L 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.09.030. PubMed
  152. Willimsky G, et al. 2021. Elife. 10:. PubMed
  153. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  154. García–Ortiz A, et al. 2017. PLoS Biol. 15:e2000653. PubMed
  155. Kujawski M, et al. 2019. BMC Cancer. 1.404166667. PubMed
  156. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  157. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  158. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  159. Dilchert J, et al. 2022. Antibodies (Basel). 11:. PubMed
  160. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  161. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  162. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  163. Fu Z, et al. 2021. Acta Pharm Sin B. 11:3925. PubMed
  164. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  165. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
  166. Xiong Y, et al. 2019. J Immunol. 203:3023. PubMed
  167. Kessel C, et al. 2017. Arthritis Rheumatol. 69:1480. PubMed
  168. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  169. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  170. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  171. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  172. Broos K, et al. 2019. Cancers (Basel). 11. PubMed
  173. Zhao R, et al. 2018. Oncoimmunology. 8:e1509173. PubMed
  174. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  175. Kim G, et al. 2021. J Infect Dis. 224:1861. PubMed
  176. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  177. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  178. Johnston HE, et al. 2018. Mol Cell Proteomics. 1.247222222. PubMed
  179. Thomi R, et al. 2017. Br J Dermatol.. 10.1111/bjd.15458. PubMed
  180. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  181. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  182. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  183. Zuñiga J, et al. 2020. Int J Infect Dis. 94:4. PubMed
  184. Wang Q, et al. 2020. J Immunother Cancer. 8:. PubMed
  185. Glud EN, et al. 2022. Br J Cancer. Online ahead of print. PubMed
  186. Mayer KE, et al. 2019. Theranostics. 4.548611111. PubMed
  187. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
  188. Alter G, et al. 2008. J Virol. 82:9668. PubMed
  189. Pinto J, et al. 2010. Immunology. 130:217. PubMed
  190. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  191. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  192. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  193. Guo J, et al. 2022. J Immunother Cancer. 10:. PubMed
  194. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  195. Rivera-Cruz CM, et al. 2022. Cytotherapy. Online ahead of print. PubMed
  196. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  197. Schoknecht T, et al. 2017. J Leukoc Biol. 101:589. PubMed
  198. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
  199. Park S, et al. 2020. Biosens Bioelectron. 112389:165. PubMed
  200. Henrick BM, et al. 2021. Cell. . PubMed
  201. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  202. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  203. Bacot SM, et al. 2020. Int J Mol Sci. 21:. PubMed
  204. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  205. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  206. Manevich-Mendelson E, et al. 2009. Blood. 114:2344. PubMed
  207. Caielli S, et al. 2019. Nat Med. 25:75. PubMed
  208. Ardain A, et al. 2019. Nature. 570:528. PubMed
  209. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  210. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  211. Carriche GM, et al. 2021. J Allergy Clin Immunol. 147:335. PubMed
  212. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  213. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  214. Meng Q, et al. 2018. Sci Rep. 8:17079. PubMed
  215. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  216. Chevalier MF, et al. 2017. J Clin Invest. 127:2916. PubMed
  217. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  218. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  219. Müller TR, et al. 2021. Cell Rep Med. 2:100374. PubMed
  220. Benabdallah B, et al. 2019. Front Immunol. 10:2580. PubMed
  221. Sneddon S, et al. 2020. Oncoimmunology. 9:1684713. PubMed
  222. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
  223. Naranbhai V, et al. 2022. Cell. . PubMed
  224. Yang J, et al. 2020. Nat Commun. 11:4402. PubMed
  225. Crome SQ, et al. 2017. Nat Med. 1.213888889. PubMed
  226. Hashimoto M, et al. 2017. Int J Inflam. 2017:1324735. PubMed
  227. Siegers GM, et al. 2020. Front Immunol. 1.352083333. PubMed
  228. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  229. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  230. He Y, et al. 2021. eLife. 10:00. PubMed
  231. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  232. Yin Y, et al. 2017. J Allergy Clin Immunol. 139:1701. PubMed
  233. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  234. Liu Z, et al. 2017. Oncotarget. 8:53518. PubMed
  235. Terzuoli E, et al. 2019. Cancers (Basel). 1.821527778. PubMed
  236. Welch JL, et al. 2020. FEBS Lett. 594:695. PubMed
  237. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  238. Shalata W, et al. 2021. Cancers (Basel). 13: . PubMed
  239. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  240. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
RRID
AB_571926 (BioLegend Cat. No. 317301)
AB_571927 (BioLegend Cat. No. 317302)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 06.12.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
OKT3 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T3, CD3ε
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT3_Purified_053107
Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
  • OKT3_Purified_053107
    Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
317301 25 µg NOK248
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317302 100 µg NOK454
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Hawley KM, et al. 2022. Proc Natl Acad Sci U S A. 119:e2209044119. PubMed
  2. Sun X, et al. 2023. Cell Death Dis. 14:242. PubMed
  3. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  4. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
  5. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  6. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  7. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  8. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  9. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  10. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  11. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  12. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  13. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  14. Jeong H, et al. 2008. J Leukoc Biol. 83:755. PubMed
  15. Biggs M, et al. 2011. J R Soc Interface. 1.348611111. PubMed
  16. Blas-Rus N, et al. 2016. Nat Commun. 7: 11389. PubMed
  17. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  18. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  19. Berkson JD, et al. 2020. Immunohorizons. 4:14. PubMed
  20. Mehta N, et al. 2020. Sci Rep. 10:15171. PubMed
  21. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  22. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  23. Bae EA, et al. 2018. Cancer Res. 78:5315. PubMed
  24. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  25. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  26. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  27. Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed
  28. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  29. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  30. Yarzabek B et al. 2018. eLife. 7 pii: e34961. PubMed
  31. Lang C, Wang J, and Chen L 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.09.030. PubMed
  32. Willimsky G, et al. 2021. Elife. 10:. PubMed
  33. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  34. García–Ortiz A, et al. 2017. PLoS Biol. 15:e2000653. PubMed
  35. Kujawski M, et al. 2019. BMC Cancer. 1.404166667. PubMed
  36. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  37. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  38. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  39. Dilchert J, et al. 2022. Antibodies (Basel). 11:. PubMed
  40. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  41. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  42. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  43. Fu Z, et al. 2021. Acta Pharm Sin B. 11:3925. PubMed
  44. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  45. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
  46. Xiong Y, et al. 2019. J Immunol. 203:3023. PubMed
  47. Kessel C, et al. 2017. Arthritis Rheumatol. 69:1480. PubMed
  48. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  49. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  50. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  51. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  52. Broos K, et al. 2019. Cancers (Basel). 11. PubMed
  53. Zhao R, et al. 2018. Oncoimmunology. 8:e1509173. PubMed
  54. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  55. Kim G, et al. 2021. J Infect Dis. 224:1861. PubMed
  56. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  57. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  58. Johnston HE, et al. 2018. Mol Cell Proteomics. 1.247222222. PubMed
  59. Thomi R, et al. 2017. Br J Dermatol.. 10.1111/bjd.15458. PubMed
  60. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  61. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  62. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  63. Zuñiga J, et al. 2020. Int J Infect Dis. 94:4. PubMed
  64. Wang Q, et al. 2020. J Immunother Cancer. 8:. PubMed
  65. Glud EN, et al. 2022. Br J Cancer. Online ahead of print. PubMed
  66. Mayer KE, et al. 2019. Theranostics. 4.548611111. PubMed
  67. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
  68. Alter G, et al. 2008. J Virol. 82:9668. PubMed
  69. Pinto J, et al. 2010. Immunology. 130:217. PubMed
  70. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  71. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  72. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  73. Guo J, et al. 2022. J Immunother Cancer. 10:. PubMed
  74. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  75. Rivera-Cruz CM, et al. 2022. Cytotherapy. Online ahead of print. PubMed
  76. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  77. Schoknecht T, et al. 2017. J Leukoc Biol. 101:589. PubMed
  78. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
  79. Park S, et al. 2020. Biosens Bioelectron. 112389:165. PubMed
  80. Henrick BM, et al. 2021. Cell. . PubMed
  81. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  82. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  83. Bacot SM, et al. 2020. Int J Mol Sci. 21:. PubMed
  84. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  85. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  86. Manevich-Mendelson E, et al. 2009. Blood. 114:2344. PubMed
  87. Caielli S, et al. 2019. Nat Med. 25:75. PubMed
  88. Ardain A, et al. 2019. Nature. 570:528. PubMed
  89. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  90. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  91. Carriche GM, et al. 2021. J Allergy Clin Immunol. 147:335. PubMed
  92. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  93. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  94. Meng Q, et al. 2018. Sci Rep. 8:17079. PubMed
  95. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  96. Chevalier MF, et al. 2017. J Clin Invest. 127:2916. PubMed
  97. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  98. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  99. Müller TR, et al. 2021. Cell Rep Med. 2:100374. PubMed
  100. Benabdallah B, et al. 2019. Front Immunol. 10:2580. PubMed
  101. Sneddon S, et al. 2020. Oncoimmunology. 9:1684713. PubMed
  102. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
  103. Naranbhai V, et al. 2022. Cell. . PubMed
  104. Yang J, et al. 2020. Nat Commun. 11:4402. PubMed
  105. Crome SQ, et al. 2017. Nat Med. 1.213888889. PubMed
  106. Hashimoto M, et al. 2017. Int J Inflam. 2017:1324735. PubMed
  107. Siegers GM, et al. 2020. Front Immunol. 1.352083333. PubMed
  108. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  109. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  110. He Y, et al. 2021. eLife. 10:00. PubMed
  111. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  112. Yin Y, et al. 2017. J Allergy Clin Immunol. 139:1701. PubMed
  113. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  114. Liu Z, et al. 2017. Oncotarget. 8:53518. PubMed
  115. Terzuoli E, et al. 2019. Cancers (Basel). 1.821527778. PubMed
  116. Welch JL, et al. 2020. FEBS Lett. 594:695. PubMed
  117. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  118. Shalata W, et al. 2021. Cancers (Basel). 13: . PubMed
  119. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  120. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
  121. Hawley KM, et al. 2022. Proc Natl Acad Sci U S A. 119:e2209044119. PubMed
  122. Sun X, et al. 2023. Cell Death Dis. 14:242. PubMed
  123. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  124. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
  125. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  126. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  127. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  128. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  129. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  130. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  131. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  132. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  133. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  134. Jeong H, et al. 2008. J Leukoc Biol. 83:755. PubMed
  135. Biggs M, et al. 2011. J R Soc Interface. 1.348611111. PubMed
  136. Blas-Rus N, et al. 2016. Nat Commun. 7: 11389. PubMed
  137. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  138. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  139. Berkson JD, et al. 2020. Immunohorizons. 4:14. PubMed
  140. Mehta N, et al. 2020. Sci Rep. 10:15171. PubMed
  141. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  142. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  143. Bae EA, et al. 2018. Cancer Res. 78:5315. PubMed
  144. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  145. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  146. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  147. Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed
  148. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  149. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  150. Yarzabek B et al. 2018. eLife. 7 pii: e34961. PubMed
  151. Lang C, Wang J, and Chen L 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.09.030. PubMed
  152. Willimsky G, et al. 2021. Elife. 10:. PubMed
  153. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  154. García–Ortiz A, et al. 2017. PLoS Biol. 15:e2000653. PubMed
  155. Kujawski M, et al. 2019. BMC Cancer. 1.404166667. PubMed
  156. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  157. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  158. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  159. Dilchert J, et al. 2022. Antibodies (Basel). 11:. PubMed
  160. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  161. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  162. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  163. Fu Z, et al. 2021. Acta Pharm Sin B. 11:3925. PubMed
  164. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  165. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
  166. Xiong Y, et al. 2019. J Immunol. 203:3023. PubMed
  167. Kessel C, et al. 2017. Arthritis Rheumatol. 69:1480. PubMed
  168. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  169. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  170. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  171. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  172. Broos K, et al. 2019. Cancers (Basel). 11. PubMed
  173. Zhao R, et al. 2018. Oncoimmunology. 8:e1509173. PubMed
  174. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  175. Kim G, et al. 2021. J Infect Dis. 224:1861. PubMed
  176. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  177. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  178. Johnston HE, et al. 2018. Mol Cell Proteomics. 1.247222222. PubMed
  179. Thomi R, et al. 2017. Br J Dermatol.. 10.1111/bjd.15458. PubMed
  180. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  181. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  182. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  183. Zuñiga J, et al. 2020. Int J Infect Dis. 94:4. PubMed
  184. Wang Q, et al. 2020. J Immunother Cancer. 8:. PubMed
  185. Glud EN, et al. 2022. Br J Cancer. Online ahead of print. PubMed
  186. Mayer KE, et al. 2019. Theranostics. 4.548611111. PubMed
  187. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
  188. Alter G, et al. 2008. J Virol. 82:9668. PubMed
  189. Pinto J, et al. 2010. Immunology. 130:217. PubMed
  190. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  191. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  192. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  193. Guo J, et al. 2022. J Immunother Cancer. 10:. PubMed
  194. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  195. Rivera-Cruz CM, et al. 2022. Cytotherapy. Online ahead of print. PubMed
  196. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  197. Schoknecht T, et al. 2017. J Leukoc Biol. 101:589. PubMed
  198. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
  199. Park S, et al. 2020. Biosens Bioelectron. 112389:165. PubMed
  200. Henrick BM, et al. 2021. Cell. . PubMed
  201. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  202. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  203. Bacot SM, et al. 2020. Int J Mol Sci. 21:. PubMed
  204. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  205. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  206. Manevich-Mendelson E, et al. 2009. Blood. 114:2344. PubMed
  207. Caielli S, et al. 2019. Nat Med. 25:75. PubMed
  208. Ardain A, et al. 2019. Nature. 570:528. PubMed
  209. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  210. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  211. Carriche GM, et al. 2021. J Allergy Clin Immunol. 147:335. PubMed
  212. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  213. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  214. Meng Q, et al. 2018. Sci Rep. 8:17079. PubMed
  215. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  216. Chevalier MF, et al. 2017. J Clin Invest. 127:2916. PubMed
  217. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  218. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  219. Müller TR, et al. 2021. Cell Rep Med. 2:100374. PubMed
  220. Benabdallah B, et al. 2019. Front Immunol. 10:2580. PubMed
  221. Sneddon S, et al. 2020. Oncoimmunology. 9:1684713. PubMed
  222. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
  223. Naranbhai V, et al. 2022. Cell. . PubMed
  224. Yang J, et al. 2020. Nat Commun. 11:4402. PubMed
  225. Crome SQ, et al. 2017. Nat Med. 1.213888889. PubMed
  226. Hashimoto M, et al. 2017. Int J Inflam. 2017:1324735. PubMed
  227. Siegers GM, et al. 2020. Front Immunol. 1.352083333. PubMed
  228. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  229. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  230. He Y, et al. 2021. eLife. 10:00. PubMed
  231. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  232. Yin Y, et al. 2017. J Allergy Clin Immunol. 139:1701. PubMed
  233. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  234. Liu Z, et al. 2017. Oncotarget. 8:53518. PubMed
  235. Terzuoli E, et al. 2019. Cancers (Basel). 1.821527778. PubMed
  236. Welch JL, et al. 2020. FEBS Lett. 594:695. PubMed
  237. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  238. Shalata W, et al. 2021. Cancers (Basel). 13: . PubMed
  239. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  240. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
RRID
AB_571926 (BioLegend Cat. No. 317301)
AB_571927 (BioLegend Cat. No. 317302)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org
Go To Top Version: 2    Revision Date: 06.12.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account